BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ: FLKS), focused on developing treatments for cramps and spasms associated with severe neurological diseases, today announced the appointment of William K. McVicar, Ph.D., as President of Research and Development. Dr. McVicar brings to Flex Pharma approximately 30 years of clinical development experience, most recently serving as Chief Scientific Officer at Inotek.
“Bill has an impressive track record of multiple drug approvals based upon his operational excellence and execution,” stated Dr. Christoph Westphal, CEO of Flex Pharma. “With their successful partnership from their time at Sepracor, Bill and our CMO, Dr. Tom Wessel, are a great team to rapidly advance our Phase 2 clinical trials in MS, ALS and Charcot-Marie-Tooth with FLX-787 which will be amongst the most advanced clinical programs in ALS and CMT.”
“I am thrilled that Bill will join us at Flex as we plan to initiate our Phase 2 trials in ALS and CMT in the United States this summer,” said Flex Pharma Chief Medical Officer Thomas Wessel, M.D., Ph.D., who served as the medical lead for three products approved in the United States: RAZADYNE®, LUNESTA® and AMPYRA®. “Bill and I know each other well and experienced many clinical trial and regulatory successes at Sepracor. His operational savvy, strategic thinking and energy are major assets to guide us through the development of FLX-787.”
"It is my great pleasure to be joining the Flex team that is applying the scientific advances of a Nobel laureate to improving the lives of patients living with debilitating neurological diseases," said Dr. McVicar. “In partnership with CMO Tom Wessel, my former Sepracor colleague, we are poised to execute on our US Phase 2 development plans.”
Prior to joining Flex Pharma, Dr. McVicar served as Executive Vice President of Pharmaceutical Development, Chief Scientific Officer, and President during his tenure at Inotek. As Vice President of Development Operations at Sepracor, he oversaw the development, FDA review, and approval of multiple NDAs and SNDAs, including BROVANA®, XOPENEX MDI®, and XOPENEX’s pediatric approval, which were each approved in a single 10-month review cycle. Prior to Sepracor, Dr. McVicar held various positions of increasing responsibility at Sandoz, Novartis and Rhone Poulenc Rorer. Dr. McVicar earned his B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair and CEO Christoph Westphal, M.D., Ph.D.

